In this section
@article{Kura:2024:cid/ciae074,
author = {Kura, K and Mutono, N and Basáñez, M-G and Collyer, BS and Coffeng, LE and Thumbi, SM and Anderson, RM},
doi = {cid/ciae074},
journal = {Clinical Infectious Diseases},
pages = {S126--S130},
title = {How does treatment coverage and proportion never treated influence the success of Schistosoma mansoni elimination as a public health problem by 2030?},
url = {http://dx.doi.org/10.1093/cid/ciae074},
volume = {78},
year = {2024}
}
TY - JOUR
AB - BackgroundThe 2030 target for schistosomiasis is elimination as a public health problem (EPHP), achieved when the prevalence of heavy-intensity infection among school-aged children (SAC) reduces to <1%. To achieve this, the new World Health Organization guidelines recommend a broader target of population to include pre-SAC and adults. However, the probability of achieving EPHP should be expected to depend on patterns in repeated uptake of mass drug administration by individuals.MethodsWe employed 2 individual-based stochastic models to evaluate the impact of school-based and community-wide treatment and calculated the number of rounds required to achieve EPHP for Schistosoma mansoni by considering various levels of the population never treated (NT). We also considered 2 age-intensity profiles, corresponding to a low and high burden of infection in adults.ResultsThe number of rounds needed to achieve this target depends on the baseline prevalence and the coverage used. For low- and moderate-transmission areas, EPHP can be achieved within 7 years if NT ≤10% and NT <5%, respectively. In high-transmission areas, community-wide treatment with NT <1% is required to achieve EPHP.ConclusionsThe higher the intensity of transmission, and the lower the treatment coverage, the lower the acceptable value of NT becomes. Using more efficacious treatment regimens would permit NT values to be marginally higher. A balance between target treatment coverage and NT values may be an adequate treatment strategy depending on the epidemiological setting, but striving to increase coverage and/or minimize NT can shorten program duration.
AU - Kura,K
AU - Mutono,N
AU - Basáñez,M-G
AU - Collyer,BS
AU - Coffeng,LE
AU - Thumbi,SM
AU - Anderson,RM
DO - cid/ciae074
EP - 130
PY - 2024///
SN - 1058-4838
SP - 126
TI - How does treatment coverage and proportion never treated influence the success of Schistosoma mansoni elimination as a public health problem by 2030?
T2 - Clinical Infectious Diseases
UR - http://dx.doi.org/10.1093/cid/ciae074
UR - https://www.ncbi.nlm.nih.gov/pubmed/38662698
UR - https://academic.oup.com/cid/article/78/Supplement_2/S126/7657836
UR - http://hdl.handle.net/10044/1/111694
VL - 78
ER -
For any enquiries related to the MRC Centre please contact:
Scientific Manager
Susannah Fisher
mrc.gida@imperial.ac.uk
External Relationships and Communications Manager
Dr Sabine van Elsland
s.van-elsland@imperial.ac.uk